Marshall Wace North America’s Quince Therapeutics QNCX Stock Holding History

Marshall Wace North America’s Portfolio QNCX Stock Details QNCX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	$9.88M	Buy	539 +260	+93%	+$4.14M	0.04%	356
2021 Q2	$2.95M	Buy	+279	New	+$2.34M	0.01%	694
2021 Q1	–	Sell	-266	Closed	-$1.48M	–	1725
2020 Q4	$1.48M	Buy	266 +56	+27%	+$496K	0.01%	837
2020 Q3	$2.1M	Sell	210 -86	-29%	-$782K	0.01%	568
2020 Q2	$2.74M	Buy	296 +108	+57%	+$990K	0.02%	501
2020 Q1	$1.72M	Sell	188 -330	-64%	-$3.26M	0.01%	514
2019 Q4	$5.81M	Buy	+518	New	+$3.12M	0.03%	365

Other funds holding QNCX

ECG

EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PHAM

Pacific Heights Asset Management San Francisco, California $3.16B AUM 42.38% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Marshall Wace North America's QNCX Position: Q3 2021 in Review

Marshall Wace North America increased its Quince Therapeutics (QNCX) stake by 93% in Q3 2021, buying an estimated $4.14M and bringing the position to 539 shares worth $9.88M. The position accounts for 0.04% of the portfolio, ranked #356.

Marshall Wace North America first reported a position in QNCX in Q4 2019 and has held it in 7 quarters since. 126 funds tracked by Wall St. Rank hold QNCX as of Q3 2021.

Marshall Wace North America held 539 shares of Quince Therapeutics worth $9.88M as of Q3 2021.
Marshall Wace North America bought 260 Quince Therapeutics shares in Q3 2021, an estimated $4.14M.
Quince Therapeutics made up 0.04% of Marshall Wace North America's portfolio in Q3 2021, its #356 holding.
Marshall Wace North America first reported a position in Quince Therapeutics in Q4 2019 and has held it in 7 quarters since.
126 funds tracked by Wall St. Rank held Quince Therapeutics as of Q3 2021.

Based on Marshall Wace North America's 13F filing for Q3 2021, filed 15 Nov 2021.